{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T18:16:03Z","timestamp":1767896163816,"version":"3.49.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2012,7,13]],"date-time":"2012-07-13T00:00:00Z","timestamp":1342137600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diabetologia"],"published-print":{"date-parts":[[2012,10]]},"DOI":"10.1007\/s00125-012-2632-z","type":"journal-article","created":{"date-parts":[[2012,7,11]],"date-time":"2012-07-11T22:47:11Z","timestamp":1342046831000},"page":"2779-2788","source":"Crossref","is-referenced-by-count":55,"title":["The glucose-lowering effects of the PDE4 inhibitors roflumilast and roflumilast-N-oxide in db\/db mice"],"prefix":"10.1007","volume":"55","author":[{"given":"S.","family":"Vollert","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Kaessner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Heuser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Hanauer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Dieckmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Knaack","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H. P.","family":"Kley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Beume","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Weiss-Haljiti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2012,7,13]]},"reference":[{"key":"2632_CR1","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.pharmthera.2005.07.003","volume":"109","author":"C Lugnier","year":"2006","unstructured":"Lugnier C (2006) Cyclic nucleotide phosphodiesterase (PDE) superfamily: a new target for the development of specific therapeutic agents. Pharmacol Ther 109:366\u2013398","journal-title":"Pharmacol Ther"},{"key":"2632_CR2","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.pupt.2010.03.011","volume":"23","author":"A Hatzelmann","year":"2010","unstructured":"Hatzelmann A, Morcillo EJ (2010) The preclinical pharmacology of roflumilast \u2013 a selective, oral phosphodiesterase 4 inhibitor in development of chronic obstructive pulmonary disease. Pulm Pharmacol Ther 23:235\u2013256","journal-title":"Pulm Pharmacol Ther"},{"key":"2632_CR3","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S0162-3109(00)00185-5","volume":"47","author":"JE Souness","year":"2000","unstructured":"Souness JE, Aldous D, Sargent C (2000) Immunosuppressive and anti-inflammatory effects of cyclic AMP phosphodiesterase (PDE) type 4 inhibitors. Immunopharmacology 47:127\u2013162","journal-title":"Immunopharmacology"},{"key":"2632_CR4","doi-asserted-by":"crossref","first-page":"3076","DOI":"10.1210\/en.2009-0108","volume":"150","author":"R Zhang","year":"2009","unstructured":"Zhang R, Maratos-Flier E, Flier JS (2009) Reduced adiposity and high-fat diet-induced adipose inflammation in mice deficient for phosphodiesterase 4B. Endocrinology 150:3076\u20133082","journal-title":"Endocrinology"},{"key":"2632_CR5","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.cell.2012.01.017","volume":"148","author":"SJ Park","year":"2012","unstructured":"Park SJ, Ahmad F, Philp A et al (2012) Resveratrol ameliorates aging-related metabolic phenotypes by inhibiting cAMP phosphodiesterases. Cell 148:421\u2013433","journal-title":"Cell"},{"key":"2632_CR6","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1016\/j.bcp.2008.07.025","volume":"76","author":"D Waddleton","year":"2008","unstructured":"Waddleton D, Wu W, Feng Y et al (2008) Phosphodiesterase 3 and 4 comprise the major cAMP metabolizing enzymes responsible for insulin secretion in INS-1 (832\/13) cells and rat islets. Biochem Pharmacol 76:884\u2013893","journal-title":"Biochem Pharmacol"},{"key":"2632_CR7","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1111\/j.1476-5381.2009.00194.x","volume":"157","author":"WK Ong","year":"2009","unstructured":"Ong WK, Gribble FM, Reimann F et al (2009) The role of the PDE4D cAMP phosphodiesterase in the regulation of glucagon-like peptide-1 release. Br J Pharmacol 157:633\u2013644","journal-title":"Br J Pharmacol"},{"key":"2632_CR8","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/j.cellsig.2009.01.015","volume":"21","author":"B Omar","year":"2009","unstructured":"Omar B, Zmuda-Trzebiatowska E, Manganiello V, G\u00f6ransson O, Degerman E (2009) Regulation of AMP-activated protein kinase by cAMP in adipocytes: roles for phosphodiesterases, protein kinase B, protein kinase A, Epac and lipolysis. Cell Signal 21:760\u2013766","journal-title":"Cell Signal"},{"key":"2632_CR9","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.cmet.2006.01.004","volume":"3","author":"DJ Drucker","year":"2006","unstructured":"Drucker DJ (2006) The biology of incretin hormones. Cell Metab 3:153\u2013165","journal-title":"Cell Metab"},{"key":"2632_CR10","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1126\/science.153.3740.1127","volume":"153","author":"KP Hummel","year":"1966","unstructured":"Hummel KP, Dickie MM, Coleman DL (1966) Diabetes, a new mutation in the mouse. Science 153:1127\u20131128","journal-title":"Science"},{"key":"2632_CR11","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1293\/tox.22.133","volume":"22","author":"M Yamazaki","year":"2009","unstructured":"Yamazaki M, Kato A, Kato C et al (2009) Segmentation of the pathophysiological stages of diabetic changes in the db\/db mouse. J Toxicol Pathol 22:133\u2013137","journal-title":"J Toxicol Pathol"},{"key":"2632_CR12","doi-asserted-by":"crossref","first-page":"236","DOI":"10.5414\/CPP47236","volume":"47","author":"G Lahu","year":"2009","unstructured":"Lahu G, H\u00fcnnemeyer A, Herzog R et al (2009) Effect of repeated dose of erythromycin on the pharmacokinetics of roflumilast and roflumilast N-oxide. Int J Clin Pharmacol Ther 47:236\u2013245","journal-title":"Int J Clin Pharmacol Ther"},{"key":"2632_CR13","doi-asserted-by":"crossref","first-page":"4521","DOI":"10.1210\/en.2009-0252","volume":"150","author":"S R\u00fctti","year":"2009","unstructured":"R\u00fctti S, Ehses JA, Sibler RA et al (2009) Low- and high-density lipoproteins modulate function, apoptosis, and proliferation of primary human and murine pancreatic beta-cells. Endocrinology 150:4521\u20134530","journal-title":"Endocrinology"},{"key":"2632_CR14","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1177\/0091270006294529","volume":"47","author":"TD Bethke","year":"2007","unstructured":"Bethke TD, B\u00f6hmer GM, Hermann R et al (2007) Dose-proportional intraindividual single- and repeated-dose pharmacokinetics of roflumilast, an oral, once-daily phosphodiesterase 4 inhibitor. J Clin Pharmacol 47:26\u201336","journal-title":"J Clin Pharmacol"},{"key":"2632_CR15","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1111\/j.1464-5491.2008.02514.x","volume":"25","author":"FM Gribble","year":"2008","unstructured":"Gribble FM (2008) RD Lawrence Lecture 2008: targeting GLP-1release as a potential strategy for the therapy of type 2 diabetes. Diabet Med 25:889\u2013894","journal-title":"Diabet Med"},{"key":"2632_CR16","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1517\/14728214.2011.616493","volume":"16","author":"A Lund","year":"2011","unstructured":"Lund A, Knop FK, Vilsb\u00f8ll T (2011) Emerging GLP-1 receptor agonists. Expert Opin Emerg Drugs 16:607\u2013618","journal-title":"Expert Opin Emerg Drugs"},{"issue":"1","key":"2632_CR17","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1111\/j.1476-5381.2011.01218.x","volume":"163","author":"K Rabe","year":"2011","unstructured":"Rabe K (2011) Update on roflumilast, a phosphodiesterase 4 inhibitor for the treatment of chronic obstructive pulmonary disease. Br J Pharmacol 163(1):53\u201367","journal-title":"Br J Pharmacol"},{"key":"2632_CR18","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.amjmed.2003.07.022","volume":"116","author":"GE Dailey","year":"2004","unstructured":"Dailey GE, Noor MA, Park JS, Bruce S, Fiedorek FT (2004) Glycemic control with glyburide\/metformin tablets in combination with rosiglitazone in patients with type 2 diabetes: a randomized double-blind trial. Am J Med 116:223\u2013229","journal-title":"Am J Med"},{"key":"2632_CR19","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1001\/jama.287.3.360","volume":"287","author":"SE Inzuchi","year":"2002","unstructured":"Inzuchi SE (2002) Oral antihyperglycemic therapy for type 2 diabetes. JAMA 287:360\u2013372","journal-title":"JAMA"},{"key":"2632_CR20","doi-asserted-by":"crossref","first-page":"165","DOI":"10.7326\/0003-4819-128-3-199802010-00001","volume":"128","author":"UK Prospective Diabetes Study Group","year":"1998","unstructured":"UK Prospective Diabetes Study Group (1998) UKPDS 24: a 6-year, randomized, controlled trial comparing sulfonylurea, insulin, and metformin therapy in patients with newly diagnosed type 2 diabetes that could not be controlled with diet therapy. Ann Intern Med 128:165\u2013175","journal-title":"Ann Intern Med"},{"key":"2632_CR21","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1210\/en.130.1.159","volume":"130","author":"HC Fehmann","year":"1992","unstructured":"Fehmann HC, Habener JF (1992) Insulinotropic hormone glucagon-like peptide-I(7-37) stimulation of proinsulin gene expression and proinsulin biosynthesis in insulinoma beta TC-1 cells. Endocrinology 130:159\u2013166","journal-title":"Endocrinology"},{"key":"2632_CR22","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.1172\/JCI117225","volume":"93","author":"DA D\u2019Alessio","year":"1994","unstructured":"D\u2019Alessio DA, Kahn SE, Leusner CR, Ensinck JW (1994) Glucagon-like peptide-1 enhances glucose tolerance both by stimulation of insulin release and by increasing insulin-independent glucose disposal. J Clin Invest 93:2263\u20132266","journal-title":"J Clin Invest"},{"key":"2632_CR23","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1007\/s00125-004-1379-6","volume":"47","author":"J Buteau","year":"2004","unstructured":"Buteau J, El-Assaad W, Rhodes CJ, Rosenberg CJ, Joly E, Prentki M (2004) Glucagon-like peptide-1 prevents beta cell glucolipotoxicity. Diabetologia 47:806\u2013815","journal-title":"Diabetologia"},{"key":"2632_CR24","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.2337\/diabetes.51.5.1443","volume":"51","author":"C Tourrel","year":"2002","unstructured":"Tourrel C, Bailbe D, Lacorne M, Meile MJ, Kergoat M, Portha B (2002) Persistent improvement of type 2 diabetes in the Goto-Kakizaki rat model by expansion of the \u00df-cell mass during the prediabetic period with glucagon-like peptide-1 or exendin-4. Diabetes 51:1443\u20131452","journal-title":"Diabetes"},{"key":"2632_CR25","doi-asserted-by":"crossref","first-page":"741","DOI":"10.2337\/diabetes.49.5.741","volume":"49","author":"DA Stoffers","year":"2000","unstructured":"Stoffers DA, Kieffer TJ, Hussain MA et al (2000) Insulinotropic glucagon-like peptide 1 agonists stimulate expression of homeodomain protein IDX-1 and increase islet size in mouse pancreas. Diabetes 49:741\u2013748","journal-title":"Diabetes"},{"key":"2632_CR26","doi-asserted-by":"crossref","first-page":"2270","DOI":"10.2337\/diabetes.48.12.2270","volume":"48","author":"G Xu","year":"1999","unstructured":"Xu G, Stoffers DA, Habener JF, Bonner-Weir S (1999) Exendin-4 stimulates both \u00df-cell replication and neogenesis, resulting in increased \u00df-cell mass and improved glucose tolerance in diabetic rats. Diabetes 48:2270\u20132276","journal-title":"Diabetes"},{"key":"2632_CR27","doi-asserted-by":"crossref","first-page":"2358","DOI":"10.2337\/diabetes.48.12.2358","volume":"48","author":"J Zhou","year":"1999","unstructured":"Zhou J, Wang X, Pineyro MA, Egan JM (1999) Glucagon-like peptide 1 and exendin-4 convert pancreatic AR42J cells into glucagon- and insulin-producing cells. Diabetes 48:2358\u20132366","journal-title":"Diabetes"},{"key":"2632_CR28","doi-asserted-by":"crossref","first-page":"E745","DOI":"10.1152\/ajpendo.00030.2002","volume":"283","author":"B Rolin","year":"2002","unstructured":"Rolin B, Larsen MO, Gotfredsen CF et al (2002) The long-acting GLP-1 derivative NN2211 ameliorates glycemia and increases \u00df-cell mass in diabetic mice. Am J Physiol Endocrinol Metab 283:E745\u2013E752","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"2632_CR29","doi-asserted-by":"crossref","first-page":"S264","DOI":"10.2337\/dc11-s223","volume":"34","author":"S Cernea","year":"2011","unstructured":"Cernea S, Raz I (2011) Therapy in the early stage: incretins. Diabetes Care 34:S264\u2013S271","journal-title":"Diabetes Care"},{"key":"2632_CR30","doi-asserted-by":"crossref","first-page":"589","DOI":"10.2165\/11536600-000000000-00000","volume":"49","author":"G Lahu","year":"2010","unstructured":"Lahu G, H\u00fcnnemeyer A, Diletti E et al (2010) Population pharmacokinetic modelling of roflumilast and roflumilast N-oxide by total phosphodiesterase-4 inhibitory activity and development of a population pharmacodynamic-adverse event model. Clin Pharmacokinet 49:589\u2013606","journal-title":"Clin Pharmacokinet"}],"container-title":["Diabetologia"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00125-012-2632-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00125-012-2632-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00125-012-2632-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,23]],"date-time":"2019-05-23T11:49:41Z","timestamp":1558612181000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00125-012-2632-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,7,13]]},"references-count":30,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2012,10]]}},"alternative-id":["2632"],"URL":"https:\/\/doi.org\/10.1007\/s00125-012-2632-z","relation":{},"ISSN":["0012-186X","1432-0428"],"issn-type":[{"value":"0012-186X","type":"print"},{"value":"1432-0428","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,7,13]]}}}